Javascript must be enabled to continue!
Patients with Monosomal Karyotype in Acute Myeloid Leukemia Is Prognostically Worse Than with Complex Karyotype
View through CrossRef
Abstract
Abstract 4735
Purpose: Monosomal karyotype (MK) refers to the presence of two or more distinct autosomal monosomies or a single monosomy associated with a structural abnormality. To analyze the prognosis of cytogenetic components of a complex karyotype or Monosomal Karyotype in acute myeloid leukemia (AML) except acute promyelocytic leukemia(APL). Patients and Methods:Cytogenetics and overall survival (OS), Disease free survival(DFS) were analyzed in 551 AML patients age 14 to 60 years in our center.Results: There ware 235 patiets with cytogenetic abnormalities, 25 cases with inv(16)(p13.1q22) or t(16;16)(p13.1;q22),and 63 cases with t(8;21); 31 cases (13.2%)met the criteria for MK and 39 cases (16.6%) had a complex karyotype without monosomies. OS was significantly inferior in patients with MK compared with those with a complex karyotype without monosomies (P<0.01;HR 1.85,95% confidence interval(95%CI),0.95-2.81). There was no difference between MK cases with complex karyotype cases in DFS (P>0.05□GHR 3.42,95% confidence interval(95%CI),2.96-6.70). There was significant difference in regardless of whether OS or DFS between MK+ patients with MK− patients (P<0.01). Conclusion: MK was one of independent risk factor in AML patients.
Disclosures:
No relevant conflicts of interest to declare.
American Society of Hematology
Title: Patients with Monosomal Karyotype in Acute Myeloid Leukemia Is Prognostically Worse Than with Complex Karyotype
Description:
Abstract
Abstract 4735
Purpose: Monosomal karyotype (MK) refers to the presence of two or more distinct autosomal monosomies or a single monosomy associated with a structural abnormality.
To analyze the prognosis of cytogenetic components of a complex karyotype or Monosomal Karyotype in acute myeloid leukemia (AML) except acute promyelocytic leukemia(APL).
Patients and Methods:Cytogenetics and overall survival (OS), Disease free survival(DFS) were analyzed in 551 AML patients age 14 to 60 years in our center.
Results: There ware 235 patiets with cytogenetic abnormalities, 25 cases with inv(16)(p13.
1q22) or t(16;16)(p13.
1;q22),and 63 cases with t(8;21); 31 cases (13.
2%)met the criteria for MK and 39 cases (16.
6%) had a complex karyotype without monosomies.
OS was significantly inferior in patients with MK compared with those with a complex karyotype without monosomies (P<0.
01;HR 1.
85,95% confidence interval(95%CI),0.
95-2.
81).
There was no difference between MK cases with complex karyotype cases in DFS (P>0.
05□GHR 3.
42,95% confidence interval(95%CI),2.
96-6.
70).
There was significant difference in regardless of whether OS or DFS between MK+ patients with MK− patients (P<0.
01).
Conclusion: MK was one of independent risk factor in AML patients.
Disclosures:
No relevant conflicts of interest to declare.
Related Results
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical...
Activation Of EphrinB2/EphB4 Influences Myeloid Leukemia Cell Migration and Invasion
Activation Of EphrinB2/EphB4 Influences Myeloid Leukemia Cell Migration and Invasion
Abstract
Eph receptors and ephrin ligands are cell-surface molecules capable of bidirectional signaling that control cell-cell interactions, migration and invasion. ...
Role of Vitamin D in the diagnosis of acute Myeloid Leukemia
Role of Vitamin D in the diagnosis of acute Myeloid Leukemia
A range of hematological and biochemical markers have been investigated in Acute Myeloid Leukemia (AML) patients to determine the relationship between cancer growth and metabolic p...
STAT3 Mutations in Large Granular Lymphocytic Leukemia
STAT3 Mutations in Large Granular Lymphocytic Leukemia
Abstract
Abstract 1606
Introduction:
Large granular lymphocytic leukemia (LGL leukemia) is a rare lymphoprolifera...
Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype
Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype
Abstract
Purpose: The recognition of a number of leukemia-specific cytogenetic abnormalities and their role as independent prognostic factors have provided considera...
Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)
Abstract
Introduction
Higher-risk myelodysplastic syndromes (MDS) progress to secondary acute myeloid leukemia (sAML) within mon...

